Uniquity Bio's CEO on exiting stealth mode with $300M in funding from its parent Blackstone to go after TSLP in the I&I space

blonca9
May 28, 2024
1 min read

Brian Lortie describes how Blackstone has launched the company and the multiple advantages this relationship brings, why TSLP, and the road ahead in terms of indications and the timing of future readouts.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Uniquity Bio's CEO on exiting stealth mode with $300M in funding from its parent Blackstone to go after TSLP in the I&I space

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight